Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multiple-Dose Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted RO5190591 in Combination With Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1
Brief Summary: This study will evaluate the efficacy, safety and tolerability of danoprevir (RO5190591) plus ritonavir as compared to danoprevir alone or placebo plus ritonavir in patients with chronic hepatitis C genotype 1 receiving Pegasys (peginterferon alfa-2a) and ribavirin. Patients in cohorts will be randomized to receive either oral doses of danoprevir, or danoprevir plus ritonavir, or placebo plus ritonavir. All patients will receive Pegasys (180mcg sc once weekly) plus ribavirin (1000-1200mg/day po), with the option to continue this treatment after completion of study drug treatment. Anticipated time on study treatment is up to 12 weeks.


Options:
A: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4, Group 5, Group 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4, Group 5, Group 6
B: Arm Label: LDV/SOF 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: LDV/SOF 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): LDV/SOF 12 weeks, LDV/SOF 24 weeks, LDV/SOF+RBV 12 weeks, LDV/SOF+RBV 24 weeks | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): LDV/SOF+RBV 12 weeks, LDV/SOF+RBV 24 weeks
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: danoprevir, Drug: peginterferon alfa-2a [Pegasys], Drug: ribavirin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: danoprevir, Drug: peginterferon alfa-2a [Pegasys], Drug: ribavirin, Drug: ritonavir | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: peginterferon alfa-2a [Pegasys], Drug: placebo, Drug: ribavirin, Drug: ritonavir | Intervention Type: DRUG; Name: danoprevir; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: peginterferon alfa-2a [Pegasys]; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: ritonavir; Assigned to Arm(s): B, C
D: Arm Label: Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Sofosbuvir | Arm Label: Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Sofosbuvir | Arm Label: Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Sofosbuvir | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks

Answer: C